Ionis Pharmaceuticals, Inc. — Q3 2023 Form 10-Q Summary
Business Context and Reporting Period
Ionis Pharmaceuticals is a biotechnology company focused on RNA-targeted therapeutics. The filing covers the quarter and nine months ended September 30, 2023, with consolidated results including wholly owned subsidiary Akcea Therapeutics. Ionis operated as a single segment and had four marketed medicines: QALSODY, SPINRAZA, TEGSEDI and WAYLIVRA.
Key Financial Metrics
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Total revenue | $144.2 million | $159.8 million | $463.1 million | $435.5 million |
| Operating expenses | $287.5 million | $218.9 million | $810.7 million | $637.7 million |
| Loss from operations | $(143.3) million | $(59.2) million | $(347.6) million | $(202.2) million |
| Net loss | $(147.4) million | $(47.0) million | $(357.0) million | $(217.3) million |
| Net loss per share | $(1.03) | $(0.33) | $(2.50) | $(1.53) |
- Q3 operating margin was approximately (99%) and net margin approximately (102%). Nine-month operating and net margins were approximately (75%) and (77%), respectively.
- Commercial revenue was $84.1 million in Q3 and $229.7 million for the nine months. SPINRAZA royalties contributed $67.3 million and $178.5 million, respectively.
- Research and development revenue was $60.1 million in Q3 and $233.4 million for the nine months. Nine-month R&D revenue benefited from partner milestones, including payments associated with AstraZeneca, Biogen and GSK.
- Research, development and patent expense increased to $215.3 million in Q3 and $643.1 million for the nine months, reflecting advancement and enrollment of late-stage clinical programs.
- SG&A expense increased to $70.0 million in Q3 and $161.6 million for the nine months, driven by commercialization preparation for eplontersen, olezarsen and donidalorsen, plus an $18 million charge related to termination of an Oceanside build-to-suit lease.
- Investment income was $23.9 million in Q3 and $63.4 million for the nine months, compared with $7.5 million and $13.4 million in the prior-year periods.
- Interest expense related to the sale of future royalties was $17.8 million in Q3 and $50.9 million for the nine months.
- Cash used in operating activities was $340.4 million for the nine months, compared with $74.2 million in the prior-year period. Cash used in investing activities was $187.4 million, while financing activities provided $603.4 million.
- Cash and cash equivalents were $352.1 million at September 30, 2023. Short-term investments were $1.884 billion, providing approximately $2.236 billion of cash, cash equivalents and short-term investments.
- Total assets were $2.934 billion, total liabilities were $2.619 billion and stockholders’ equity was $315.5 million. Accumulated deficit was $1.787 billion.
Material Changes Versus Prior Comparable Period
- Q3 revenue declined 10% year over year because of timing of collaborative revenue, particularly the absence of a $35 million Roche license fee recognized in Q3 2022. Nine-month revenue increased 6%.
- Q3 net loss more than tripled year over year, primarily because operating expenses rose substantially while revenue declined. Nine-month net loss increased by $139.7 million.
- Ionis received a $500 million upfront payment from Royalty Pharma in January 2023 for a portion of future SPINRAZA and pelacarsen royalties. The transaction was recorded as a liability rather than revenue.
- Royalty Pharma is entitled to 25% of SPINRAZA royalties from 2023 through 2027, increasing to 45% in 2028, and 25% of future pelacarsen royalties, subject to the agreement’s terms.
- Ionis issued $575 million of 1.75% convertible senior notes due 2028 and repurchased approximately $504.4 million principal amount of 0.125% convertible notes. The remaining principal balance of the 0.125% notes was $44.5 million at quarter-end.
- Debt outstanding included $575.0 million of 1.75% notes, $632.5 million of 0% notes due 2026 and $44.5 million of 0.125% notes due 2024.
- The company recorded a $13.4 million gain on early retirement of debt for the nine months.
- Ionis terminated an Oceanside manufacturing facility lease and recorded an $18 million SG&A charge. Management stated that the termination was not expected to impair commercialization plans, but the company still expects to expand manufacturing capacity in the future.
- QALSODY received accelerated FDA approval in April 2023. Eplontersen’s U.S. NDA was under review with a December 22, 2023 PDUFA date. Ionis reported positive Phase 3 Balance results for olezarsen and planned regulatory filings in 2024.
- In August and September 2023, Ionis entered into new collaboration agreements with Novartis and Roche. Each partner paid a $60 million upfront amount in October 2023; these payments were not included in September 30, 2023 cash balances or reported revenue.
- Ionis’ North American TEGSEDI distribution agreement with Sobi was terminated in October 2023.
Guidance, Outlook, Commentary and Risks
- Management expected operating expenses, excluding non-cash stock compensation, to increase slightly in the fourth quarter of 2023 as late-stage development and commercialization preparations continued.
- Ionis had nine medicines in Phase 3 studies for eleven indications, including eplontersen, olezarsen, donidalorsen, ulefnersen, pelacarsen, bepirovirsen, IONIS-FB-L Rx and zilganersen.
- The company expects to continue funding operations with cash, cash equivalents and short-term investments, but may pursue equity, debt, refinancing, credit lines or additional collaborations depending on business performance and financing conditions.
- Royalty Pharma’s effective interest rate was estimated at 13.5% at September 30, 2023. Changes in SPINRAZA sales, pelacarsen approval or sales, competition and other factors could materially alter future royalty payments and related interest expense.
- Key risks include continued operating losses, substantial clinical and commercialization spending, dependence on collaboration partners, regulatory and clinical trial uncertainty, reimbursement and pricing pressure, competition, manufacturing capacity and supply-chain constraints, intellectual-property risks, product safety, cybersecurity and geopolitical disruption.
- Contractual obligations totaled approximately $1.598 billion, including convertible debt, leases, mortgage obligations and other commitments. The filing excludes the liability related to the sale of future royalties from this table.
- The filing reported no pending material legal proceedings, no off-balance-sheet arrangements and effective disclosure controls as of September 30, 2023.
Important Facts for Investors to Verify
- Whether eplontersen received U.S. regulatory approval by the December 22, 2023 PDUFA date and the timing and economics of any launch.
- Progress and regulatory outcomes for olezarsen, donidalorsen, QALSODY, pelacarsen, bepirovirsen, IONIS-FB-L Rx, ulefnersen and zilganersen.
- SPINRAZA royalty trends, QALSODY commercial uptake and the effect of competition on royalty revenue.
- The financial impact of the Royalty Pharma agreement, including the 13.5% estimated effective interest rate, future royalty remittances and eligibility for up to $625 million of additional milestone payments.
- Liquidity relative to the company’s operating cash burn, approximately $1.598 billion of disclosed contractual obligations and the $632.5 million of 0% convertible notes due in 2026.
- The replacement strategy, timing and cost of expanded manufacturing capacity following termination of the Oceanside facility lease.
- The commercial and financial effect of terminating Sobi’s North American TEGSEDI distribution agreement.